Support | Portal

Impact Explorer & Heliogram™

View your data in insightful, contextually relevant, and engaging ways across multiple areas of interest. Leverage Metabolon’s knowledge base for truly insightful views of deeply annotated metabolomic data.

Our proprietary Heliogram™ visualization enables you to see deep within the metabolic pathway impacts and their associated effects on human health. Easily compare up to six study groups at a time for pathway impact, significance, and associations. Change how you visualize metabolomics with the richest and most biologically relevant database of metabolite annotations.

Visualization Legend

Outer Ring: Metabolites

The outer ring of the Heliogram™ visualization consists of the metabolites in the Discovery Panel. The outer ring can show up to six statistical comparisons at a time, allowing you to compare your results and view trends or contrasts.

Inner Ring: Associations

The inner ring of the Heliogram™ visualization consists of annotation-based associations.  Each node represents an association, ordered alphabetically. The bar next to each node shows the percentage of significant results within the association.

Choose Your View

Comparisons
P-Value Threshold
Search
Associations

The outer ring of the Heliogram™ visualizes statistical comparisons (one group compared to another) for each metabolite in the Discovery Panel. Select which comparison(s) to view by using the “Select Comparison” drop-down menu. Here you will see the group comparisons defined by your study design. You can select up to six comparisons to view at once, arranged and ordered by the sequence of their selection.

This slider allows you to adjust the limit of statistical significance (p-value) shown in the visualization and classification tables. Sliding to the right will widen the range of significance, while sliding to left will narrow the range to only the most statistically significant metabolites for the chosen comparison.

p-values for each comparison are derived from the natural log-transformed data using the corresponding statistical analysis (e.g., t-Test, ANOVA, etc.).

Use this drop-down to find or search for a particular metabolite or association from within the Discovery Panel. Once selected, the metabolite or association will be highlighted within the visualization.

Hovering over any heatmap square or metabolite circle brings that metabolite into view. A border appears around the heatmap squares, while all other squares fade into the background. A line (or set of lines) is drawn to connect the metabolite to its association(s). The center shows the name of the metabolite. Additionally, a table appears in the center that lists out the associations related to the selected metabolite. The table includes a percent significant (% sig) metric. This is calculated by taking all the metabolites related to the association (and not just the one hovered over) and all the comparisons within view and counting how many are significant. For example, if the association of ‘pathway a’ was associated with 2 metabolites and 6 comparisons were selected, the denominator would be 12 (2 x 6). The numerator would be calculated by taking how many of the 12 comparisons were significant, such as 3. This means the metric would show 3 / 12 or 25%. The purpose of this metric is to see if the metabolite hovered over has similar results to other related metabolites.

Hovering over an association circle or bar brings that association into view. A set of lines are drawn from the association to the related metabolites. The related metabolites are left full opacity, while everything else fades. The names of the metabolites are added around the outside of the visualization. The name of the association appears in the center. Additionally, a table appears listing out the associated metabolites. The table includes a ‘total significant’ metric. This is calculated by counting how many of the comparisons in view are significant (p-value less than p-value threshold). For example, if 3 of 6 were significant, the total significant would show 3.

See how Metabolon can advance your path to preclinical and clinical insights

Contact Us

Talk with an expert

Request a quote for our services, get more information on sample types and handling procedures, request a letter of support, or submit a question about how metabolomics can advance your research.

Corporate Headquarters

617 Davis Drive, Suite 100
Morrisville, NC 27560

Mailing Address:
P.O. Box 110407
Research Triangle Park, NC 27709

+1 (919) 572-1721

References

1. Zgoda-Pols, J.R., et al., Metabolomics analysis reveals elevation of 3-indoxyl sulfate in plasma and brain during chemically-induced acute kidney injury in mice: investigation of nicotinic acid receptor agonists. Toxicol Appl Pharmacol, 2011. 255(1): p. 48-56.

2. Bryant, J.A., et al., The impact of an oral purified microbiome therapeutic on the gastrointestinal microbiome. Nat Med, 2026. 32(1): p. 186-196

3. McGovern, B .H., et al., SER-109, an Investigational Microbiome Drugto Reduce Recurrence After Clostridioides difficile Infection: Lessons Learned From a Phase 2 Trial. Clin Infect Dis, 2021. 72(12): p. 2132-2140.

4. Feuerstadt, P., et al., SER-109, an Oral Microbiome Therapy for Recurrent Clostridioides difficile Infection. N Engl J Med, 2022. 386(3): p. 220-229.

5. Hu, Z., et al., Targeted metabolomics reveals novel diagnostic biomarkers for colorectal cancer. Mol Oncol, 2025. 19(6): p. 1737-1750.

6. Butler, F.M., et al., Vegetarian Dietary Patterns and Diet-Related Metabolites Are Associated With Kidney Function in the Adventist Health Study-2 Cohort. J Ren Nutr, 2025.

7. Stanford, J., et al., Metabolomic Profiling and Diet Quality Scoring in a Randomized Crossover Trial of Healthy and Typical Dietary Patterns. Mol Nutr Food Res, 2025 . 69(23): p. e70271.

8. O’Connor, L.E., et al., Metabolomic Profiling of an Ultraprocessed Dietary Pattern in a Domiciled Randomized Controlled Crossover Feeding Trial. J Nutr, 2023. 153(8): p. 2181-2192.

9. Fritsch, D.A., et al., Microbiome function underpins the efficacy of a fiber-supplemented dietary intervention in dogs with chronic large bowel diarrhea. BMC Vet Res, 2022. 18(1): p. 245.

10. Leal, L.N., et al., Preweaning nutrient supply improves lactation productivity and reduces the risk of culling in Holstein cows. J Dairy Sci, 2025. 108(6): p. 5875-5888.

11. Ahsin, M., et al., Soil and pasture health underlie improved beef nutrient density determined by untargeted metabolomics in Southern US grass finished beef systems. NPJ Sci Food, 2025. 9(1): p. 151.

12. Yin, W., et al., Plasma lipid profiling across species for the identification of optimal animal models of human dyslipidemia. J Lipid Res, 2012. 53(1): p. 51-65.

13. Porter, F .D., et al., Cholesterol oxidation products are sensitive and specific blood-based biomarkers for Niemann-Pick C1 disease. Sci Transl Med, 2010. 2(56): p. 56ra81.

14. Needham, B .D., et al., Plasma and Fecal Metabolite Profiles in Autism Spectrum Disorder. Biol Psychiatry, 2021. 89(5): p. 451-462

15. Li, C., et al., Estradiol and mTORC2 cooperate to enhance prostaglandin biosynthesis and tumorigenesis in TSC2-deficient LAM cells. J Exp Med, 2014. 211(1): p. 15-28.

16. Green, P.G., et al., Metabolic flexibility and reverse remodelling of the failing human heart. Eur Heart J, 2025. 46(25): p. 2422-2433.

17. Maekawa, H., et al., SGLT2 inhibition protects kidney function by SAM-dependent epigenetic repression of inflammatory genes under metabolic stress. J Clin Invest, 2025. 135(19).

18. Wu, D., et al., Integrated screens reveal that guanine nucleotide depletion, which is irreversible via targeting IMPDH2, inhibits pancreatic cancer and potentiates KRAS inhibition. Gut, 2026.

19. Schwerdtfeger, L.A., et al., Gut microbiota and metabolites are linked to disease progression in multiple sclerosis. Cell Rep Med, 2025. 6(4): p. 102055.

20. Wu, H., et al., Microbiome-metabolome dynamics associated with impaired glucose control and responses to lifestyle changes. Nat Med, 2025. 31(7): p. 2222-2231.

21. Jacobs, J.P., et al., Cognitive behavioral therapy for irritable bowel syndrome induces bidirectional alterations in the brain-gut-microbiome axis associated with gastrointestinal symptom improvement. Microbiome, 2021. 9(1): p. 236.

22. Pietzner, M., et al., Plasma metabolites to profile pathways in noncommunicable disease multimorbidity. Nat Med, 2021. 27(3): p. 471-479.

23. Faquih, T.O., et al., Robust Metabolomic Age Prediction Based on a Wide Selection of Metabolites. J Gerontol A Biol Sci Med Sci, 2025. 80(3).

24. Scherer, N., et al., Coupling metabolomics and exome sequencing reveals graded effects of rare damaging heterozygous variants on gene function and human traits. Nat Genet, 2025. 57(1): p. 193-205.

25. Holmes, Z.C., et al., Untargeted metabolomic analysis of human milk from healthy mothers reveals drivers of metabolite variability. Sci Rep, 2024. 14(1): p. 20827.

26. Titz, B., et al., Implications of Ocular Confounding Factors for Aqueous Humor Proteomic and Metabolomic Analyses in Retinal Diseases. Transl Vis Sci Technol, 2024. 13(6): p. 17.

27. Bloom, S.M., et al., Cysteine dependence of Lactobacillus iners is a potential therapeutic target for vaginal microbiota modulation. Nat Microbiol, 2022. 7(3): p. 434-450.

28. Leimer, E.M., et al., Lipid profile of human synovial fluid following intra-articular ankle fracture. J Orthop Res, 2017. 35(3): p. 657-666.